相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
Alessio Malacrida et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dong-Rui Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway
Farzad Rahmani et al.
CELLULAR SIGNALLING (2021)
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
Alessio Malacrida et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Anti-tumor effects of rigosertib in high-risk neuroblastoma
Katarzyna Radke et al.
TRANSLATIONAL ONCOLOGY (2021)
Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
Marco Jost et al.
MOLECULAR CELL (2020)
Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma
Huan Ma et al.
ONCOLOGY RESEARCH (2020)
Current Diagnosis and Management of Small-Cell Lung Cancer
Shuhang Wang et al.
MAYO CLINIC PROCEEDINGS (2019)
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic dual-hit option
Peter Dietrich et al.
ONCOTARGET (2018)
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
Shyamala C. Navada et al.
LEUKEMIA RESEARCH (2018)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
Marco Jost et al.
MOLECULAR CELL (2017)
Lung Cancer: Understanding its Molecular Pathology and the 2015 WHO Classification
Kentaro Inamura
FRONTIERS IN ONCOLOGY (2017)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes
Shyamala C. Navada et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit
Daniel A. Ritt et al.
MOLECULAR CELL (2016)
The RAS/MAPK Axis Gets Stressed Out
Scott A. Foster et al.
MOLECULAR CELL (2016)
ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines
Anil Prasad et al.
ONCOTARGET (2016)
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic canceraEuro
B. H. O'Neil et al.
ANNALS OF ONCOLOGY (2015)
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
Tomoko Hyoda et al.
CANCER SCIENCE (2015)
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and PIk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Daniel W. Bowles et al.
CLINICAL CANCER RESEARCH (2014)
Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, In Vitro and In Vivo
Lorenzo Agoni et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
Feng Xu et al.
SCIENTIFIC REPORTS (2014)
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910•Na (Rigosertib®), a phase III clinical stage anti-cancer agent
Venkat R. Pallela et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2013)
ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Colby M. Chapman et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Wen Wee Ma et al.
CLINICAL CANCER RESEARCH (2012)
Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 Hyperphosphorylation
Irina A. Oussenko et al.
CANCER RESEARCH (2011)
Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure-Activity Relationship, and Biological Activity
M. V. Ramana Reddy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay
A. Jimeno et al.
ONCOGENE (2009)
分享论文
